Core Viewpoint - A class action has been filed against uniQure N.V. for allegedly misleading investors regarding the FDA approval likelihood of its leading drug candidate, AMT-130 [1] Allegations - The complaint alleges that uniQure did not fully disclose that the design of its Pivotal Study was not fully approved by the FDA [1] - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline to conduct additional studies [1] Impact of FDA Feedback - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from the Phase I/II studies of AMT-130 would be adequate for BLA submission [1] - Following this announcement, uniQure's stock price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1] Class Action Participation - Shareholders wishing to serve as lead plaintiffs must submit their papers by April 13, 2026 [1] - Participation in the case is not required to be eligible for recovery, and representation is on a contingency fee basis [1]

Core Viewpoint - A class action lawsuit has been filed against Kyndryl Holdings, Inc. for allegedly materially misstating its financial statements and lacking adequate internal controls, leading to a significant drop in stock price [1] Group 1: Allegations - The lawsuit claims that Kyndryl's financial statements during the class period were materially misstated [1] - It is alleged that Kyndryl lacked adequate internal controls and materially understated issues related to these controls [1] - The company failed to file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025, in a timely manner [1] Group 2: Impact on Stock Price - Following the announcement of the late filing and the SEC investigation, Kyndryl's stock price fell by $12.90 per share, or 55%, closing at $10.59 on February 9, 2026 [1] Group 3: Legal Proceedings - Shareholders wishing to serve as lead plaintiffs must submit their papers to the court by April 13, 2026 [1] - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [1]

Core Viewpoint - A class action has been filed against Paysafe Limited (NYSE: PSFE) for allegedly misleading investors about its business prospects during the specified period [1][2]. Group 1: Allegations - The complaint alleges that Paysafe's ecommerce business had significant exposure to a single high-risk client [2] - It is claimed that the company's credit loss reserves and/or write-offs were understated due to this exposure [2] - Paysafe reportedly faced undisclosed issues with higher risk Merchant Category Codes, complicating its client services [2] - These issues were likely to negatively impact the company's revenue growth and overall revenue mix [2] - As a result, Paysafe was unlikely to meet its previously issued financial guidance for fiscal year 2025 [2] Group 2: Market Reaction - Following the revelation of these issues, Paysafe's stock price fell by $2.80, or 27.6%, closing at $7.36 per share on November 13, 2025 [3] Group 3: Legal Proceedings - Shareholders wishing to serve as lead plaintiff in the class action must submit their papers by April 7, 2026 [4] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Group 4: Company Background - Robbins LLP is recognized as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5]

Core Viewpoint - A class action has been filed against Vistagen Therapeutics, Inc. for allegedly misleading investors regarding the viability of its Phase 3 trial study of fasedienol, leading to significant financial losses for shareholders [1][2]. Group 1: Class Action Details - The class action is on behalf of all investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025 [1][2]. - Allegations include that Vistagen provided misleading statements about the success of its Phase 3 PALISADE-3 trial for fasedienol while concealing material adverse facts [2][3]. Group 2: Trial Results and Impact - On December 17, 2025, Vistagen announced that the PALISADE-3 study did not show statistically significant improvement on the primary endpoint, leading to a dramatic stock price decline from $4.36 to $0.86, a drop of over 80% [3]. Group 3: Next Steps for Investors - Shareholders wishing to serve as lead plaintiffs must submit their papers by March 16, 2026, and can choose to remain absent class members if they do not wish to participate [4].

SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Fermi Inc. (NASDAQ: FRMI): (a) common stock pursuant to the registration statement issued in connection with the Company's October 2025 initial public offering ("IPO"); or (b) securities between October 25, 2025 and December 11, 2025. Fermi purports to be an energy and artificial intelligence (“AI”) infrastructure company. For more informa ...

Core Viewpoint - Robbins LLP is reminding investors of a class action lawsuit against BellRing Brands, Inc. (NYSE: BRBR) for allegedly misleading investors about its sales performance during the class period from November 19, 2024, to August 4, 2025 [1] Group 1: Allegations and Company Performance - The lawsuit alleges that BellRing Brands misled investors by presenting strong sales results that did not reflect genuine consumer demand, but rather an accumulation of excess inventory by customers [1] - Following the resolution of previous product shortages, customers reduced their inventory, leading to a decline in new orders and a subsequent admission from the company that competitive pressures were weakening demand [1] - On August 4, 2025, BellRing reported a disappointing fiscal Q3 2025 outlook, narrowing its net sales forecast for the fiscal year 2025 to a range of $2.28 billion to $2.32 billion [1] Group 2: Stock Price Impact - Following the negative sales outlook announcement, BellRing's stock price fell by $17.46 per share, a decline of nearly 33%, from $53.64 on August 4, 2025, to $36.18 on August 5, 2025 [1]

Core Viewpoint - A class action has been filed against Masonite International Corporation (NYSE: DOOR) for allegedly misleading investors regarding its acquisition by Owens Corning's Doors, particularly concerning undisclosed offers and share repurchases [1] Group 1: Allegations and Misconduct - The class action arises from claims that Masonite made material omissions and misrepresentations about Owens Corning's offers to purchase all outstanding common stock at significant premiums [1] - Masonite repurchased nearly 270,000 shares for approximately $25 million between June 2023 and December 2023, while failing to disclose Owens Corning's offers for about eight months [1] - During the class period, Masonite made misleading statements about its share buyback activities, claiming they were meant to distribute capital back to investors without disclosing the higher offers from Owens Corning [1] Group 2: Stock Price Impact - Following the announcement of the arrangement agreement on February 9, 2024, Masonite's stock price surged to $130.51, reflecting a 35.1% increase from the previous trading day's close [1] Group 3: Legal Proceedings - Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 7, 2026, and participation is not required to be eligible for recovery [1] - Robbins LLP, the firm leading the class action, operates on a contingency fee basis, meaning shareholders incur no fees or expenses [1]

Core Viewpoint - A class action has been filed against Inovio Pharmaceuticals, Inc. for allegedly misleading investors regarding the approval process for its CELLECTRA device and the INO-3107 Biologics License Application (BLA) [1] Group 1: Allegations and Issues - The complaint alleges that Inovio failed to disclose deficiencies in the manufacturing of its CELLECTRA device [1] - It is claimed that Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024 due to these manufacturing issues [1] - The company reportedly lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review [1] Group 2: Impact on Stock Price - Following a press release on August 8, 2024, revealing a delay in the INO-3107 BLA submission to mid-2025, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 per share on August 9, 2024 [1] - On December 29, 2025, after announcing that the FDA accepted the INO-3107 BLA on a standard review timeline, Inovio's stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 per share [1] Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Inovio, with a deadline to submit papers to the court by April 7, 2026 [1] - The lead plaintiff will represent other class members in directing the litigation, but participation is not required for recovery [1]

POM Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against POMDoctor Ltd. [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- [Robbins LLP] reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China."For more information ...

Core Viewpoint - A class action has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the Phase III Orbit and Cosmic Studies for setrusumab, which tested its efficacy in treating Osteogenesis Imperfecta [1][2]. Group 1: Allegations and Misleading Information - The complaint alleges that Ultragenyx provided overly positive statements about setrusumab's expected results, claiming it would decrease the annualized fracture rate in patients with Osteogenesis Imperfecta [2]. - Defendants are accused of concealing material adverse facts about setrusumab's potential and the risks associated with the study protocols, specifically that while setrusumab increases bone density, it does not correlate with a decrease in fracture rates [3]. Group 2: Study Results and Stock Impact - On December 29, 2025, Ultragenyx announced that the Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonates [4]. - Following this announcement, Ultragenyx's stock price plummeted from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in one day [4]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Ultragenyx and can contact Robbins LLP if they wish to serve as lead plaintiff [5]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [5].